Bangladesh Class B, C, D: Notified Body QMS and Design Certification

1. Key takeaways

Conformity assessment for Class B, C and D devices in Bangladesh must pass through a notified body. §4.6 of the DGDA Medical Device Registration Guidelines provides that devices at the moderate-to-high risk levels require quality management system (QMS) certification issued by a notified body, and that Class D additionally requires device design certification. §4.8 then makes the cost position explicit: fees arising from assessment and certification are borne by the manufacturer. The practical effect is that the notified body relationship is not a supporting document in a Bangladeshi file but a precondition of the file existing at all.

• Notified body involvement is mandatory for Class B, C and D, not discretionary.
• QMS certification covers all three classes; design certification is an additional requirement for Class D alone.
• The manufacturer carries the assessment and certification fees.
• Overseas certificates must be submitted for consideration rather than being automatically accepted.
• ISO 13485 is the reference standard for the quality system, alongside the essential requirements.

2. Legal basis

The guideline sections work as a sequence. Section 4.6 sets the assessment requirement, §4.7 governs evidence already held abroad, §4.8 allocates cost, §4.9 covers sampling and verification, and §7.1 anchors the standards. The last row of the table below is drawn from registration practice rather than from the guidelines, and is labelled as such.

3. Expert insights

Insight one: CE marking is a necessary condition, not a sufficient one. The practical document list requires an EC certificate and CE marking for Class B, C and D, and an EC design examination certificate for Class D. Holding those documents clears the evidence threshold, but it does not close the review. The most common ground for rejection at the recipe approval stage is an incomplete document set, typically a missing CE certificate or a missing reference country CFS. The distinction matters commercially, because a manufacturer with a strong European file naturally assumes that the Bangladeshi file inherits that strength. It does not. CE marking has to be written into the project expectation as an input rather than as an outcome. The review tests the file as a set, so strength in one document does not compensate for an absence in another.

Insight two: §4.7 is a reuse-of-evidence provision, but it operates as a mandatory submission rather than an optional waiver. The provision states that a manufacturer which has already obtained QMS and product certification abroad, or a marketing authorisation abroad, must submit those documents for the DGDA to consider. Overseas certificates are therefore not taken as automatically accepted; they enter the file as material on which the DGDA forms its own judgement. Chinese-language material often describes CE marking as opening a simplified channel. In Bangladesh there is no corresponding simplified channel wording, and a project plan built on the assumption that one exists will misstate both the review and the timeline. The provision is better read as a disclosure duty that runs alongside the notified body requirement, not as a substitute for it. Read that way, the section costs a manufacturer nothing except the discipline of assembling certificates it already holds.

Insight three: the Class D design certification requirement is where Bangladesh departs from most Southeast Asian markets. Registration files in Thailand, Vietnam, the Philippines and Indonesia generally call for ISO 13485, but do not require design certification as a separate item. Bangladesh requires a design examination certificate in addition for Class D, which raises the technical documentation threshold for the highest-risk products by one full step. That is one of the reasons why Class D projects carry the longest timelines and the highest cost in this market, and it is foreseeable at the quoting stage rather than at the review stage. Manufacturers who discover the requirement only after a deficiency letter lose the option of choosing the evidence route deliberately.

4. Practical recommendations

• Run a design documentation review before a Class D project starts, covering design verification and validation records, risk management files and clinical evaluation material, and test whether they hold together as a system rather than as a set of separate documents.
• Treat the design examination certificate as the constraint, not the CE certificate. Obtaining the certificate is rarely the difficulty; assembling the documentation chain behind it is.
• Where a manufacturer holds ISO 13485 but no EC design examination certificate issued by a European notified body, present the choice before submission rather than after a rejection: pursue the European route, or rely on other reference country evidence accepted by the DGDA.
• Prepare the §4.7 evidence in full, including overseas notified body certificates and any overseas marketing authorisation, and submit it rather than holding it in reserve.
• Budget the notified body assessment fees as a separate line, since §4.8 places them on the manufacturer and they are not part of any government fee. Where an agent quotes a single all-in figure, ask which party is actually contracting with the notified body.

5. Verification checklist

• □ Class confirmed as B, C or D, with notified body involvement required
• □ Class B and C: notified body QMS certification obtained, to ISO 13485
• □ Class D: EC design examination certificate obtained
• □ Overseas NRA or notified body certificates and overseas marketing authorisations prepared under §4.7
• □ Notified body assessment fees carried as a separate budget line, per the manufacturer obligation in §4.8

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com